Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
REHOVOT, Israel, Feb. 27, 2017 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences:
- Cowen and Company 37th Annual Health Care Conference taking place in Boston, Massachusetts from March 6 – 8, 2017. Dr. Lieberman’s presentation will take place on Monday, March 6 at 2:00pm ET.
- 29th Annual ROTH Conference taking place in Dana Point, California from March 12 – 15, 2017. Dr. Lieberman’s presentation will take place on Tuesday, March 14 at 9:00am PT, 12:00pm ET.
To access the live webcast of the presentation, please visit ir.neuroderm.com/. A replay will be available for a limited time following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm is headquartered in the Rabin Science Park, Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
[email protected]
Tel.: +972-8-946 2729;
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1768
